A formyl peptide receptor agonist suppresses inflammation and bone damage in arthritis

British Journal of Pharmacology

Volumn 171, Issue 17, 2014, Pages 4087-4096

  Kao, W ^a,b   Gu, R ^a   Jia, Y ^a,c   Wei, Xuemin ^a,d   Fan, H ^a   Harris, J ^a   Zhang, Zhiyi ^d   Quinn, J ^a,e   Morand, E F ^a   Yang, Y H ^a  

^a MONASH UNIVERSITY   (Australia)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^d THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^e MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; COMPOUND 43; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR 2; FORMYLPEPTIDE RECEPTOR AGONIST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOCORTIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; FORMYL PEPTIDE RECEPTOR 2, MOUSE; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DESTRUCTION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; AGONISTS; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANNEXIN A1; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BONE AND BONES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENYLUREA COMPOUNDS; PYRAZOLES; RECEPTORS, FORMYL PEPTIDE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84905985090     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12768     Document Type: Article

References (36)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et-al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
2. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et-al. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324.
3. Bartok B, Firestein GS, (2010). Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 233: 233-255.
4. Bena S, Brancaleone V, Wang JM, Perretti M, Flower RJ, (2012). Annexin A1 interaction with the FPR2/ALX receptor: identification of distinct domains and downstream associated signaling. J Biol Chem 287: 24690-24697.
5. Burli RW, Xu H, Zou X, Muller K, Golden J, Frohn M, et-al. (2006). Potent hFPRL1 (ALXR) agonists as potential anti-inflammatory agents. Bioorg Med Chem Lett 16: 3713-3718.
6. Chiang N, Serhan CN, Dahlen SE, Drazen JM, Hay DW, Rovati GE, et-al. (2006). The lipoxin receptor ALX: potent ligand-specific and stereoselective actions in vivo. Pharmacol Rev 58: 463-487.
7. Dufton N, Hannon R, Brancaleone V, Dalli J, Patel HB, Gray M, et-al. (2010). Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 184: 2611-2619.
8. Forsman H, Onnheim K, Andreasson E, Dahlgren C, (2011). What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin A4? Scand J Immunol 74: 227-234.
9. Goulding NJ, Dixey J, Morand EF, Dodds RA, Wilkinson LS, Pitsillides AA, et-al. (1995). Differential distribution of annexins-I, -II, -IV, and -VI in synovium. Ann Rheum Dis 54: 841-845.
10. Hannon R, Croxtall JD, Getting SJ, Roviezzo F, Yona S, Paul-Clark MJ, et-al. (2003). Aberrant inflammation and resistance to glucocorticoids in annexin 1-/- mouse. FASEB J 17: 253-255.
11. Ishida N, Hayashi K, Hoshijima M, Ogawa T, Koga S, Miyatake Y, et-al. (2002). Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator. J Biol Chem 277: 41147-41156.
12. Jia Y, Morand EF, Song W, Cheng Q, Stewart A, Yang YH, (2013). Regulation of lung fibroblast activation by annexin A1. J Cell Physiol 228: 476-484.
13. Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, et-al. (1999). Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids. Arthritis Rheum 42: 1601-1608.
14. Lim LH, Pervaiz S, (2007). Annexin 1: the new face of an old molecule. FASEB J 21: 968-975.
15. Monach PA, Mathis D, Benoist C, (2008). The K/BxN arthritis model. In:, Coligan JE, (ed.). Current Protocols in Immunology. John Wiley & Sons, Inc: Hoboken, New Jersey, pp. 15.22.1-15.22.12.
16. Morand EF, Hall P, Hutchinson P, Yang YH, (2006). Regulation of annexin I in rheumatoid synovial cells by glucocorticoids and interleukin-1. Mediators Inflamm 2006: 73835-73840.
17. Parente L, Solito E, (2004). Annexin 1: more than an anti-phospholipase protein. Inflamm Res 53: 125-132.
18. Patel HB, Kornerup KN, Sampaio AL, D'Acquisto F, Seed MP, Girol AP, et-al. (2012). The impact of endogenous annexin A1 on glucocorticoid control of inflammatory arthritis. Ann Rheum Dis 71: 1872-1880.
19. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et-al. (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Research 42 (Database Issue): D1098-1106.
20. Perretti M, D'Acquisto F, (2009). Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 9: 62-70.
21. Perretti M, Chiang N, La M, Fierro IM, Marullo S, Getting SJ, et-al. (2002). Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med 8: 1296-1302.
22. Sampey AV, Hutchinson P, Morand EF, (2000). Annexin I surface binding sites and their regulation on human fibroblast-like synoviocytes. Arthritis Rheum 43: 2537-2542.
23. Santos LL, Fan H, Hall P, Ngo D, Mackay CR, Fingerle-Rowson G, et-al. (2011). Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice. Arthritis Rheum 63: 960-970.
24. Singh PP, van der Kraan AG, Xu J, Gillespie MT, Quinn JM, (2012). Membrane-bound receptor activator of NFkappaB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors. Biochem Biophys Res Commun 422: 48-53.
25. Sogawa Y, Shimizugawa A, Ohyama T, Maeda H, Hirahara K, (2009). The pyrazolone originally reported to be a formyl peptide receptor (FPR) 2/ALX-selective agonist is instead an FPR1 and FPR2/ALX dual agonist. J Pharmacol Sci 111: 317-321.
26. Sogawa Y, Ohyama T, Maeda H, Hirahara K, (2011). Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist: indication of cross-desensitization in vivo. Immunology 132: 441-450.
27. Toh M, Yang YH, Leech MT, Santos LL, Morand EF, (2004). Expression of mitogen-activated protein kinase phosphatase 1, a negative regulator of mitogen-activated protein kinases, in rheumatoid arthritis: up-regulation by interleukin-1beta and glucocorticoids. Arthritis Rheum 50: 3118-3128.
28. Walther A, Riehemann K, Gerke V, (2000). A novel ligand of the formyl peptide receptor: annexin I regulates neutrophil extravasation by interacting with the FPR. Mol Cell 5: 831-840.
29. Wang C, Steer JH, Joyce DA, Yip KH, Zheng MH, Xu J, (2003). 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. J Bone Miner Res 18: 2159-2168.
30. Yang Y, Hutchinson P, Morand EF, (1999). Inhibitory effect of annexin I on synovial inflammation in rat adjuvant arthritis. Arthritis Rheum 42: 1538-1544.
31. Yang YH, Morand EF, Getting SJ, Paul-Clark M, Liu DL, Yona S, et-al. (2004). Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis. Arthritis Rheum 50: 976-984.
32. Yang YH, Toh ML, Clyne CD, Leech M, Aeberli D, Xue J, et-al. (2006). Annexin 1 negatively regulates IL-6 expression via effects on p38 MAPK and MAPK phosphatase-1. J Immunol 177: 8148-8153.
33. Yang YH, Aeberli D, Dacumos A, Xue JR, Morand EF, (2009). Annexin-1 regulates macrophage IL-6 and TNF via glucocorticoid-induced leucine zipper. J Immunol 183: 1435-1445.
34. Yang YH, Morand E, Leech M, (2013a). Annexin A1: potential for glucocorticoid sparing in RA. Nat Rev Rheumatol 9: 595-603.
35. Yang YH, Song W, Deane JA, Kao W, Ooi JD, Ngo D, et-al. (2013b). Deficiency of annexin A1 in CD4 + T cells exacerbates T cell-dependent inflammation. J Immunol 190: 997-1007.
36. Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, et-al. (2009). International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 61: 119-161.